Literature DB >> 9520143

Increased systemic toxicity of sarcoma chemotherapy due to combination with the P-glycoprotein inhibitor cyclosporin.

J G Theis1, H S Chan, M L Greenberg, D Malkin, V Karaskov, I Moncica, G Koren, J Doyle.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9520143

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN： 0946-1965            Impact factor:   1.366


× No keyword cloud information.
  4 in total

1.  Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein).

Authors:  Laura M Hodges; Svetlana M Markova; Leslie W Chinn; Jason M Gow; Deanna L Kroetz; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-03       Impact factor: 2.089

Review 2.  Clinical Implications of P-Glycoprotein Modulation in Drug-Drug Interactions.

Authors:  Marie Lund; Tonny Studsgaard Petersen; Kim Peder Dalhoff
Journal:  Drugs       Date:  2017-05       Impact factor: 9.546

3.  Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium.

Authors:  Matthew D Troutman; Dhiren R Thakker
Journal:  Pharm Res       Date:  2003-08       Impact factor: 4.200

4.  Nanomicellar paclitaxel increases cytotoxicity of multidrug resistant breast cancer cells.

Authors:  Hayat Onyüksel; Eunjung Jeon; Israel Rubinstein
Journal:  Cancer Lett       Date:  2008-11-20       Impact factor: 8.679
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.